Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat - The effect of AT1-R blocker on the hepatic fibrosis

Creative Commons License

Tuncer I., Ozbek H., Ugras S., Bayram I.

EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, cilt.55, ss.159-166, 2003 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 55
  • Basım Tarihi: 2003
  • Doi Numarası: 10.1078/0940-2993-00309
  • Dergi Adı: EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.159-166
  • Van Yüzüncü Yıl Üniversitesi Adresli: Hayır

Özet

Background/Aim: Angiotensin converting enzyme (ACE) and angiotensin II (AT-II) have been suggested to play an important role in liver fibrogenesis. There is a significant relationship between inheritance of hightened expression of transforming growth factor beta1 (TGF-beta1) and AT-II and the development of progressive hepatic fibrosis. The purpose of this study was to investigate the effects of captopril. an ACE inhibitor and candesartan cilexetil, an AT-II type I receptor (AT1-R) blocker, on liver fibrosis induced in rats by carbon tetrachloride (CCl4) administration.